Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Key transplantation updates at EHA 2021

Arnon Nagler • 14 Jun 2021
EHA 2021
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia CAR-T
ZUMA-3

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, talks on key updates in the field of stem cell transplantation at EHA 2021, in particular highlighting a study which investigated the prediction of transplantation outcomes in acute lymphoblastic leukemia (ALL) using a novel scoring system which incorporated disease status, phenotype and measurable residual disease (MRD) assessment. Prof. Nagler also comments on advances in the management of graft-versus-host disease (GvHD) and novel drugs for the prevention of relapse after transplantation. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals